Library
topharvestcap.comCrawled Oct 15, 2026
Homepage
1 pageCoverage
4 items- ClarityCare Raises $16.3M in Series A Fundingfinsmes.com/2026/10/claritycare-raises-16-3m-in-series-a-funding.html
ClarityCare secures $16.3 million in Series A funding to advance its healthcare administrative and workflow automation platform. The San Francisco-based company develops tools aimed at streamlining healthcare operations. The funding round signals growing investor interest in digital health solutions.
Oct 2026FinSMEsNews article
- Bioptimus primed with $35m to unravel disease biology using AIlongevity.technology/news/bioptimus-primed-with-35m-to-unravel-disease-biology-using-ai/
Bioptimus, a French AI-driven biology startup founded by former Google DeepMind researchers, secures $35 million in funding. The company targets the creation of a universal AI foundation model to decode disease biology. Its approach leverages deep learning to analyze biological data and uncover insights into disease mechanisms.
Feb 2024Longevity.TechnologyNews article
- Hedera Dx nabs €14 million to accelerate global adoption of liquid biopsiestech.eu/2022/09/21/hedera-dx-nabs-eur14-million-to-accelerate-global-adoption-of-liquid-biopsies/
Swiss biotech **Hedera Dx** secures **€14 million** in funding to expand its blood-based liquid biopsy platform. The solution allows hospital labs to perform **clinically actionable cancer diagnostics in-house**, matching patients with approved therapies. This streamlines treatment decisions by eliminating delays in external testing.
Sep 2022Tech.euNews article
- Attempting to make liquid biopsies a reality, Hedera Dx snaps €14M for less invasive cancer detection — TFNtechfundingnews.com/attempting-to-make-liquid-biopsies-a-reality-hedera-dx-snaps-e14m-for-less-invasive-cancer-detection/
Hedera Dx secures €14 million in funding to advance liquid biopsy technology, enabling less invasive cancer detection. The company focuses on developing non-invasive methods to identify cancer through blood samples, aiming to improve early diagnosis and patient outcomes. This funding supports further research and commercialization of its innovative approach in oncology.
Sep 2022Tech Funding NewsNews article
